Drugs that contain Roflumilast
1. Daliresp patents expiration
DALIRESP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(9 months ago) | |
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(9 months ago) | |
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(3 months from now) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(3 months from now) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(3 months from now) | |
Market Authorisation Date: 28 February, 2011
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL
How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage
DALIRESP family patents
2. Zoryve patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793796 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 29, 2025 |
Market Authorisation Date: 29 July, 2022
Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)
Dosage: CREAM;TOPICAL
More Information on Dosage
ZORYVE family patents